英文名称 | CAS号 | 中文名 | 中文别名 | 分子式 | 分子量 | EINECS号 |
---|---|---|---|---|---|---|
Brivanib (BMS-540215)
|
649735-46-6 |
酪氨酸激酶抑制剂
|
1-[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并[2,1-f][1,2,4]三嗪-6-基]氧基]-2-丙醇;BMS540215;BMS 540215;CS-75;布立尼布杂质;1-[[4-[(4-氟-2-甲基-1H-吲哚-5-基)氧基]-5-甲基吡咯并[2,1-F][1,2,4]三嗪-6-基]氧基]-2-丙醇;布立尼布;布立尼布、BMS-540215;酪氨酸激酶抑制剂
|
C19H19FN4O3 |
370.382 | |
CP-466722
|
1080622-86-1 |
CP466722
|
CP466722;CP 466722;CP-466722;CP-466722>98%;CS-73;CP-466722;CP466722;1-(6,7-二甲氧基-4-喹唑啉基)-3-(2-吡啶基)-1H-1,2,4-三唑-5-胺
|
C17H15N7O2 |
349.35 | 808-414-0 |
CHIR 98014
|
556813-39-9 |
CHIR 9814
|
CT98014;N6-[2-[[4-(2,4-Dichlorophenyl)-5-(1H-iMidazol-2-yl)-2-pyriMidinyl]aMino]ethyl]-3-nitro-
2,6-pyridinediaMine;N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,;N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine;N2-(2-((4-(2,4-Dichlorophenyl)-5-(1H-imidazol-2-yl)pyrimidin-2-yl)amino)ethyl)-5-nitropyridine-2,6-diamine;CHIR 98014
|
C20H17Cl2N9O2 |
486.31408 | |
PHA-848125 (Milciclib)
|
802539-81-7 |
PHA-848125
|
4,5-二氢-N,1,4-四甲基-8-[[4-(4-甲基-1-哌嗪基)苯基]氨基]-1H-吡唑并[4,3-H]喹唑啉-3-甲酰胺
|
C25H32N8O |
460.59 | |
Danoprevir (RG7227)
|
850876-88-9 |
丹诺普韦
|
RG72277;Itmn-191 Danoprevir;(2R,6S,13aS,14aR,16aS,E)-6-((tert-butoxycarbonyl)aMino)-14a-((cyclopropylsulfonyl)carbaMoyl)-5,16-dioxo-1,2,3,5,6,7,8,9,10,11,13a,14,14a,15,16,16a-hexadecahydrocyclopropa[e]pyrrolo[1,2-a][1,4]diazacyclopentadecin-2-yl 4-fluoroisoindoline-2-carboxylate;R7227;RG7227;RO5190591;Danoprevir (RG7227);Danoprevir(ITMN-191, RG7227)
|
C35H46FN5O9S |
||
GW788388
|
452342-67-5 |
GW788388
|
CS-59;4-[4-[3-(吡啶-2-基(-1H-吡唑-4-基]吡啶-2-基]-N-(四氢吡喃-4-基(苯甲酰胺;GW788388;GW 788388
|
C25H23N5O2 |
425.48242 | |
CCT137690
|
1095382-05-0 |
CCT-13769
|
3-[[4-[6-溴-2-[4-(4-甲基哌嗪-1-基)苯基]-3H-咪唑并[4,5-B]吡啶-7-基]哌嗪-1-基]甲基]-5-甲基异恶唑;CS-56;CCT-137690;CCT137690
|
C26H31BrN8O |
551.5 | |
GSK2126458
|
1086062-66-9 |
GSK2126458; GSK-2126458
|
2,4-二氟-n-[2-甲氧基-5-[4-(4-吡嗪)-6-喹啉]-3-吡啶]苯磺酰胺;CS-55;GSK2126458;GSK-2126458;2,4-二氟-N-[2-甲氧基-5-[4-(4-哒嗪基)-6-喹啉基]-3-吡啶基]苯磺酰胺;2,4-二氟-N-[2-甲氧基-5-[4-(4-吡嗪)-6-喹啉]-3-吡啶]苯磺酰胺;HYR-582;GSK2126458 (GSK458);GSK458;GSK-212;GSK-2126458;OMIPALISIB,一种有效的高度选择性PI3K抑制剂
|
C25H17F2N5O3S |
505.4959864 | 629-873-1 |
valspodar
|
121584-18-7 |
伐司扑达
|
伐司扑达;戊司泊达
|
C36H70N4O5 |
638.9648 | 1312995-182-4 |
1-cyclopropyl-3-[(3Z)-3-[5-(morpholin-4-ylmethyl)benzimidazol-2-ylidene]-1,2-dihydropyrazol-4-yl]urea
|
896466-04-9 |
AT9283
|
CS-48;AT-9283;AT 9283;1-环丙基-3-(3-(5-(吗啉甲基)-1H-苯并[D]咪唑-2-基)-1H-吡唑-4-基)脲
|
C19H23N7O2 |
381.43162 | |
ZM 336372
|
208260-29-1 |
ZM 336372
|
ZM 336372;ZM-336372;ZINC00581684;3-(二甲基氨基)-N-[3-[(4-羟基苯甲酰基)氨基]-4-甲基苯基]苯甲酰胺;ZM 336372;ZM-336372
|
C23H23N3O3 |
389.45 | |
XL147
|
956958-53-5 |
XL147
|
N-[3-(2,1,3-苯并噻二唑-5-氨基)-2-喹喔啉基]-4-甲基苯磺酰胺;N-[3-(苯并[C] [1,2,5]噻二唑-5-基氨基)喹喔啉-2-基]-4-甲基苯磺酰胺;XL147 类似物
|
C21H16N6O2S2 |
448.52074 | |
PF-04929113 (SNX-5422)
|
908115-27-5 |
SNX-5422
|
甘氨酸反式-4-[[2-(氨基羰基)-5-[4,5,6,7-四氢-6,6-二甲基-4-氧代-3-(三氟甲基)-1H-吲唑-1-基]苯基]氨基]环己酯;SNX5422;PF 04929113;SNX 5422;PF-04929113;
|
C25H30F3N5O4 |
521.53201 | |
KU-0063794
|
938440-64-3 |
KU-63794
|
5-[2-[(2R,6S)-2,6-二甲基-4-吗啉基]-4-(4-吗啉基)吡啶并[2,3-D]嘧啶-7-基]-2-甲氧基苯甲醇;CS-28;KU-0063794;KU 0063794;KU0063794
|
C25H31N5O4 |
465.551 | |
PP242
|
1092351-67-1 |
PP242
|
2-(4-氨基-1-异丙基-1H-吡唑并[3,4-D]嘧啶-3-基)-1H-吲哚-5-醇;CS-19;2-(4-氨基-1-异丙基-1H-吡唑并[3,4-D]嘧啶-3-基)-1H-吲哚-5-醇
|
C16H16N6O |
308.35 | |
AR-42 (HDAC-42)
|
935881-37-1 |
AR-42
|
CS-15;(S)-(+)-N-羟基-4-(3-甲基-2-苯基丁酰氨基)苯甲酰胺
|
C18H20N2O3 |
312.363 | 802-219-4 |
LY2784544
|
1229236-86-5 |
LY 2784544
|
CS-13;LY2784544盐酸巴多昔芬;3-[(4-氯-2-氟苯基)甲基]-2-甲基-N-(5-甲基-1H-吡唑-3-基)-8-(4-吗啉甲基)咪唑并[1,2-B]哒嗪-6-胺
|
C23H25ClFN7O |
469.95 | |
AMG 900
|
945595-80-2 |
AMG 9
|
N-[4-[[3-(2-氨基-4-嘧啶基)-2-吡啶基]氧基]苯基]-4-(4-甲基-2-噻吩基)-1-酞嗪胺;AMG-900;AMG900
|
C28H21N7OS |
503.59 | |
Kauniolide
|
81066-45-7 |
KAUNIOLIDE
|
CS-1319
|
C15H18O2 |
230.3 | |
Catharanthine sulfate
|
70674-90-7 |
硫酸长春质碱
|
硫酸长春质碱对照品;硫酸长春质碱(标准品);CS-698;硫酸长春质碱
|
C21H26N2O6S |
434.51 |